title: Treatment of asymptomatic pulmonary cryptococcosis in immunocompetent hosts with oral fluconazole.
abstract: BACKGROUND
  Pulmonary cryptococcosis is occasionally detected on routine imaging studies in healthy hosts with no or mild symptoms. Isolated pulmonary cryptococcosis may be observed without specific therapy in asymptomatic immunocompetent hosts. However, considering that dissemination from a pulmonary infection can occur in patients with no immunologic defects, treatment of asymptomatic pulmonary cryptococcosis in immunocompetent hosts remains controversial. The aim of this study was to determine the role of fluconazole therapy in the management of isolated pulmonary cryptococcosis in asymptomatic healthy hosts.
  
  
  METHODS
  We retrospectively analyzed the medical records and radiographic findings of 10 healthy subjects with isolated pulmonary cryptococcosis diagnosed incidentally and treated with oral fluconazole.
  
  
  RESULTS
  All patients had no respiratory or constitutional symptoms. The most common radiological findings were pulmonary nodules, and the number of nodules in each patient was from 1 to 9. After histological confirmation, all patients were treated with oral fluconazole at a dosage of 400 mg per day for a median period of 6.4 months. No patient developed an adverse reaction to fluconazole. The mean interval between the initiation of antifungal therapy and final radiological response was 8.3 months. Seven of the 10 patients showed complete resolution, and the other 3 patients were assessed as having partial resolution. During the average follow-up period of 11.9 months, all patients showed a favourable outcome with no relapse. The overall cure rate was 70%.
  
  
  CONCLUSIONS
  These results suggest that fluconazole may be an attractive therapeutic option for asymptomatic pulmonary cryptococcosis in immunocompetent hosts.
authors.affiliation: Department of Internal Medicine, Research Centre for Pulmonary Disorders, Chonbuk National University Medical School, Jeonju, South Korea.
authors.forename: Kyoung Hwa
authors.initials: KH
authors.lastname: Choi
authors.forename: Seoung Ju
authors.initials: SJ
authors.lastname: Park
authors.forename: Kyung Hoon
authors.initials: KH
authors.lastname: Min
authors.forename: So Ri
authors.initials: SR
authors.lastname: Kim
authors.forename: Min Hee
authors.initials: MH
authors.lastname: Lee
authors.forename: Chi Ryang
authors.initials: CR
authors.lastname: Chung
authors.forename: Hyo Jin
authors.initials: HJ
authors.lastname: Han
authors.forename: Yong Chul
authors.initials: YC
authors.lastname: Lee
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000276:immunology; D058345:Asymptomatic Infections / Q000628:therapy*; D003453:Cryptococcosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology; D003455:Cryptococcus neoformans / Q000187:drug effects* / Q000472:pathogenicity; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007121:Immunocompetence; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D008172:Lung Diseases, Fungal / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D000946:Antigens, Fungal; D015725:Fluconazole